{"id":"ap-325","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL4302313","moleculeType":"Small molecule","molecularWeight":"307.43"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the SGLT2 receptor, AP-325 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"AP-325 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:34.298Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05160272","phase":"PHASE2","title":"Effects of GABAA Receptor Modulation by AP-325 on Insulin Secretion in Patients with Type 2 Diabetes","status":"COMPLETED","sponsor":"The Deutsche Diabetes Forschungsgesellschaft e.V.","startDate":"2022-01-07","conditions":"Type2 Diabetes","enrollment":38},{"nctId":"NCT04429919","phase":"PHASE2","title":"AP-325 in Subjects With Peripheral Post-surgical Neuropathic Pain","status":"COMPLETED","sponsor":"Algiax Pharmaceuticals GmbH","startDate":"2020-06-22","conditions":"Peripheral Post-surgical Neuropathic Pain","enrollment":99}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AP-325","genericName":"AP-325","companyName":"The Deutsche Diabetes Forschungsgesellschaft e.V.","companyId":"the-deutsche-diabetes-forschungsgesellschaft-e-v","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AP-325 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}